Cilengitide

INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment

Retrieved on: 
Thursday, May 14, 2020
Clinical medicine, Cancer treatments, Medicine, Branches of biology, Brain tumor, Prodrugs, Schering-Plough, Temozolomide, Teratogens, O-6-methylguanine-DNA methyltransferase, Glioma, Cilengitide

These data will be featured at an oral poster presentation at the ASCO 2020 Virtual Scientific Program, May 29-31, 2020.

Key Points: 
  • These data will be featured at an oral poster presentation at the ASCO 2020 Virtual Scientific Program, May 29-31, 2020.
  • Currently, the median overall survival with standard of care therapy, which includes radiation and chemotherapy (temozolomide: TMZ), is approximately 15 to 22 months.
  • The Phase 1/2 clinical trial demonstrated that 84.4% percent (27 of 32) of patients with MGMT promoter unmethylated tumors, and 85% (17 of 20) of patients with MGMT promoter methylated tumors were alive at 12 months.
  • The majority of patients tested had a T cell immune response to one or more tumor-associated antigens encoded by INO-5401.